 | The topic of this article may not meet Wikipedia's
general notability guideline. (September 2023) |
 | This article needs additional citations for
verification. (September 2023) |
Avecia, a part of Nitto Denko Inc., is a private biotechnology company focused on oligonucleotide production. [1] Avecia has two facilities, one near Boston, MA, and the second in Cincinnati, OH. [1] In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals. [2]
References
- ^ a b Kansteiner, Fraiser (March 31, 2021). "Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market". Fierce Pharma. Retrieved June 3, 2024.
- ^ "Nitto Denko Avecia Inc acquires businesses of Irvine Pharmaceutical Services, Avrio Biopharmaceuticals". Reuters. October 11, 2016. Retrieved June 3, 2024.
External links
| The topic of this article may not meet Wikipedia's
general notability guideline. (September 2023) |
| This article needs additional citations for
verification. (September 2023) |
Avecia, a part of Nitto Denko Inc., is a private biotechnology company focused on oligonucleotide production. [1] Avecia has two facilities, one near Boston, MA, and the second in Cincinnati, OH. [1] In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals. [2]
References
- ^ a b Kansteiner, Fraiser (March 31, 2021). "Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market". Fierce Pharma. Retrieved June 3, 2024.
- ^ "Nitto Denko Avecia Inc acquires businesses of Irvine Pharmaceutical Services, Avrio Biopharmaceuticals". Reuters. October 11, 2016. Retrieved June 3, 2024.